fda approves semaglutide for cardiovascular risk reduction FDA approves obesity drug that

Indirect Systemic Effects Whether the cardiovascular benefits of GLP-1RAs depend on direct receptor activation in vascular and myocardial tissue or are mediated by indirect systemic effects on adipose-tissue inflammation, hepatic lipid handling, neurohumoral tone, and intestinal signaling remains incompletely resolved

Protecting Muscle While Losing Weight on GLP-1 Therapy Rapid weight loss can include loss of lean mass unless you prioritize protein and resistance training

UFC9010/UFC8010) and applied to an equilibrated HiLoad 16/600 Superdex 75 pg or 200 pg column (Cytiva Germany GmbH, Freiburg DE)

Retrieved March 15, 2025, from National Health Service

It's particularly important if patients are above 70 years of age or have liver and kidney issues

They would also need to be modified so that they can stay in the bloodstream long enough to be effective, which Pentelutes lab is also working on